Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.
Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.
The conversation discusses reducing scalp DHT to prevent hair loss, with a focus on using dutasteride, finasteride, and other treatments like RU58841 and minoxidil. It highlights the challenges of managing hair loss while on high testosterone levels, suggesting that dutasteride may be more effective than finasteride in such cases.
Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.
Switching from topical to oral minoxidil due to scalp irritation and unsatisfactory results, while also seeking cheaper options in the U.S. Oral minoxidil is generally favored for its effectiveness and fewer application downsides, with CostPlusDrugs and GoodRx offering affordable prices.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
Fluridil degrades androgenreceptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
Dutasteride may inhibit androgenreceptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.
The conversation discusses topical androgenreceptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
RU and Pyri block androgenreceptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.
Fluridil may decrease the number of androgenreceptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.
The efficacy of degrading the androgenreceptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
Ketoconazole shampoo is primarily used to reduce scalp fungus and inflammation, not to block DHT or androgenreceptors. It may help with seborrheic dermatitis and improve scalp health, but its effects on hair loss are minimal compared to treatments like finasteride.
Researching and developing an effective local antagonist to block the androgenreceptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.
A 24-year-old male experienced an increase in estradiol levels and symptoms like gynecomastia and excessive sweating after using Minoxidil for hair loss. His estradiol levels decreased after he stopped using Minoxidil.
Creatine may cause increased hair shedding due to androgenreceptor sensitivity, despite limited evidence. The user is using dutasteride and minoxidil and seeks advice on whether shedding will stabilize, with suggestions including GHK-Cu and RU58841.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgenreceptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
Theaflavin, a black tea extract, may inhibit DHT and androgenreceptor activity, but its effectiveness for hair loss is debated. Users report no significant improvement with theaflavin, while some find beta sitosterol helpful.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgenreceptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
The conversation discusses androgenreceptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
Pyrilutamide and RU58841 are androgenreceptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.
Bicalutamide blocks androgenreceptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.